A comprehensive meta-analysis by Kristensen et al. (2019) found that GLP-1 RAs reduced MACE by 12% compared to placebo, with significant reductions in cardiovascular mortality, fatal or non-fatal stroke, and fatal or non-fatal myocardial infarction (MI) [17]. This evidence concerns the gene GLP1R and myocardial infarction.